CTOs on the Move

Eupraxia Pharmaceuticals

www.eupraxiapharma.com

 
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Balt

BALT is a world leader in the design and manufacture of interventional neuroradiology devices to treat neurovascular pathologies (strokes, aneurysms, AVMs).

Rocky Mountain CARES

Rocky Mountain CARES – HIV / AIDS Advocacy Group – Denver, Colorado

Fougera Pharmaceuticals

Fougera Pharmaceuticals is a Melville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Galderma Canada

Galderma Canada Inc. is a Thornhill, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OrphoMed Inc

OrphoMed is a San Francisco based clinical stage pharmaceutical company focused on the development of novel first-in-class dimer conjugates with superior therapeutic profiles. The company is leveraging its proprietary dimer platform technology to address the issues of visceral hypersensitivity and hypermotility in functional gastrointestinal disorders. OrphoMed dimers are protected by composition of matter and method of use patents.